IDEAYA rises after lung cancer drug combo testing deal with AstraZeneca

IDEAYA Biosciences

09/04/2026 11:15

** Shares of biotech firm IDEAYA Biosciences IDYA.O rise 2% to $31.50 premarket

** Co says it will test its experimental drug IDE849 with AstraZeneca’s AZN.L Imfinzi in patients with extensive-stage small cell lung cancer, an aggressive form of lung cancer that spreads quickly

** Co says IDEAYA will lead the early-stage trial, while AstraZeneca will supply Imfinzi, an already approved immunotherapy cancer drug

** IDYA says IDE849 is also being tested in other hard-to-treat cancers, including certain neuroendocrine tumors and melanoma, in a global early-stage study

** Adds the combination targets a major unmet need, but cautions IDE849 is still in early testing and may not succeed in later studies

** As of last close, stock down ~10% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))